Table 1.
Clinicopathologic characteristics of surgical cohort by upgrading status
| Overall | Upgraded | Nonupgraded | p value | |
|---|---|---|---|---|
| n (%) | 950 (100.0) | 292 (30.7) | 658 (69.3) | |
| Age, yr, mean | 58.3 | 59.5 | 57.8 | <0.001 |
| 1st quartile ≤53, n (%) | 239 (25.2) | 57 (19.6) | 182 (27.7) | <0.001 |
| 2nd quartile 53–58, n (%) | 237 (25.0) | 62 (21.3) | 175 (26.6) | |
| 3rd quartile 58–64, n (%) | 272 (28.7) | 102 (35.1) | 170 (25.9) | |
| 4th quartile ≥64, n (%) | 200 (21.1) | 70 (24.1) | 130 (19.8) | |
| Median serum PSA, ng/ml | 4.7 | 5 | 4.5 | <0.001 |
| 0–2.5, n (%) | 101 (10.7) | 15 (5.1) | 86 (13.1) | <0.001 |
| 2.5–4, n (%) | 189 (20.0) | 49 (16.8) | 140 (21.4) | |
| 4–10, n (%) | 600 (63.3) | 200 (68.5) | 400 (61.1) | |
| >10, n (%) | 57 (6.0) | 28 (9.6) | 29 (4.4) | |
| Median prostate volume, ml | 46 | 45.1 | 46.5 | 0.22 |
| Median PSA density, ng/ml/cm3 prostate | 0.10 | 0.11 | 0.09 | <0.001 |
| Pathologic Gleason score, n (%) | ||||
| 6 | 658 (69.3) | 0 | 658 (100.0) | <0.001 |
| 7 | 277 (29.2) | 277 (94.9) | 0 | |
| 8–10 | 15 (1.6) | 15 (5.1) | 0 | |
| Pathologic stage, ≤pT2, n (%) | 834 (88.0) | 224 (77.0) | 610 (92.8) | <0.001 |
| >pT2, n (%) | 114 (12.0) | 67 (23.0) | 47 (7.2) | |
| Extracapsular extension, n (%) | 99 (10.4) | 61 (20.9) | 38 (5.8) | <0.001 |
| Seminal vesicle invasion, n (%) | 14 (1.5) | 12 (4.1) | 2 (0.3) | <0.001 |
| Positive surgical margins, n (%) | 114 (12.0) | 51 (17.5) | 63 (9.6) | <0.001 |
| Lymph node metastases, n (%) | 0 (0.0) | 0 | 0 | – |
| Median follow-up, mo | 49 | 51 | 49 | 0.50 |
PSA = prostate-specific antigen.